Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | DM919 |
| Synonyms | |
| Therapy Description |
DM919 is a monoclonal antibody that binds to membrane and soluble MICA/B, resulting in increased cell surface expression and decreased serum MICA/B levels, which potentially leads to increased NKG2D-dependent activation of NK cells and tumor growth inhibition (Journal for ImmunoTherapy of Cancer 2023;11:1355). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| DM919 | DM919 is a monoclonal antibody that binds to membrane and soluble MICA/B, resulting in increased cell surface expression and decreased serum MICA/B levels, which potentially leads to increased NKG2D-dependent activation of NK cells and tumor growth inhibition (Journal for ImmunoTherapy of Cancer 2023;11:1355). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06328673 | Phase I | DM919 DM919 + Pembrolizumab | A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors | Recruiting | USA | 1 |